NICE says no to conditionally-approved Pixuvri
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is not recommending Cell Therapeutics' Pixuvri (pixantrone) for non-Hodgkin B-cell lymphoma. In preliminary draft guidance issued 11 April, the institute says there is not enough evidence to support the drug.